Skip to content

Intravenous tranexamic acid ("TXA") and its effect on post-operative pain and stiffness in patients undergoing total shoulder arthroscopy and rotator cuff repair.

Effect of systemic tranexamic acid use on post-operative pain and stiffness in patients undergoing shoulder arthroscopy and rotator cuff repair.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617001074381
Enrollment
98
Registered
2017-07-25
Start date
2017-11-09
Completion date
2020-03-09
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This will be a multicentre multisurgeon prospective doubleblinded randomized and controlled trial looking at the effectiveness of single dose intravenous administration of Tranexamic Acid (TXA) in patients undergoing shoulder arthroscopy and rotator cuff repair. The aim of this study is to extend Level I category evidence of the known benefits of TXA to shoulder arthroscopy and rotator cuff repair. The primary objective of this study is to test the hypothesis that systemic use of tranexamic acid decreases postoperative pain and stiffness. All consecutive patients presenting to an elective orthopaedic consultation indicated for shoulder arthroscopy and rotator cuff repair will be considered eligible for this study. After having been screened for inclusion and exclusion criteria, read the information sheet and signed the consent form, patients will be blindly randomized to one of 2 groups: Systemic TXA or Control. Patients’ general demographic characteristics such as age, sex, dominance, diagnosis and other relevant comorbidities will be collected in a deidentified database locked on a password-protected computer. During the surgery, patients will be administered either 2000mg of intravenous TXA or a placebo equivalent (saline solution). Analysed outcome variables will include: occurrence of postoperative haematoma, postoperative pain Visual Analog Scale (pVAS), range of motion at 8 weeks and 24 weeks.

Interventions

Sponsors

Dr Benjamin Cass
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients who have consented for shoulder arthroscopy and rotator cuff repair under one of the investigators. 2. Patients who are capable of and have given informed consent for their participation in this study.

Exclusion criteria

1. Patients allergic to tranexamic acid 2. Patients with a failed rotator cuff repair requiring revision 3. Patients with history of deep venous thrombosis or pulmonary embolism 4. Patients with cardiovascular disease, including coronary disease or peripheral arteriopathy 5. Patients with renal or liver failure 6. Patients with a known coagulopathy 7. Patients that refuse a potential transfusion

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026